🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareComparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide — need advice Page 4

Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide — need advice

emily_PDX Mon, Jul 22, 2024 at 4:07 PM 36 replies 2,470 viewsPage 4 of 8
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Jul 24, 2024 at 1:36 AM#16

From the other side of the consultation, briefly.

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing. Semaglutide:

  • Tmax: 24-72 hours post-injection
  • T½: ~168 hours (7 days) — enables weekly dosing
  • Steady state: reached at 4-5 weeks
  • Bioavailability (SubQ): ~89%
  • Volume of distribution: ~12.5L (primarily plasma)

The albumin binding (>99%) is the key pharmacological innovation — creating a sustained-release effect from a single injection. Previous GLP-1 agonists (exenatide) required BID dosing due to rapid clearance.

33 8emily_PDX, Dr.SleepRoch, laura_annarbor and 30 others
Reply Quote Save Share Report
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Jul 24, 2024 at 5:50 AM#17

Adding the clinical framing, because it changes how the question reads.

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].

Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.

Early-stage data — interpret with caution. But the trajectory is extraordinary.

References:
[1] Novo Nordisk investor presentation, September 2023.
32 7TinaHashiRN, robert_kc, dan_philly and 29 others
Reply Quote Save Share Report
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Jul 24, 2024 at 10:04 AM#18
EndoResFellow said:
Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Second this. Posting only so the count is not one.

31 6cory_ATX, lori_vegas, Dr.PulmRoch and 28 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
WendyG_ATL
Member
1,023
5,678
Apr 2024
Georgia
Jul 24, 2024 at 2:18 PM#19
EndoResFellow said:
Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Coming at EndoResFellow’s question from a different direction. The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

30 5AttorneyGrant, DebRD_ATL, KristenIndy and 27 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jul 24, 2024 at 6:32 PM#20

Moderator note: a couple of off-topic posts removed.

8 8PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 5 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register